LEFKOFSKY ERIC P sold $17.6M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $70.36 ($67.36–$72.31, $17.59M total) across 24 trades on 2026-10-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Oct 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosure provides fresh, material information about insider activity, which can affect short‑term price dynamics.

02

Market read

Insider sales of this magnitude are noteworthy for traders monitoring Tempus AI's stock.

03

What to watch

Potential tax planning or diversification needs may drive the sale, not negative outlook.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Tempus AI filed a Form 4 on Oct 29, 2026 disclosing a 10b5‑1 sale by its CEO.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 250,000 shares for $17.6M, reducing his stake to 50,000 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $17.6M open‑market sale by the CEO is material and fresh, suggesting potential downside.

Market effects

Minimal; the sale is company‑specific and does not materially affect the AI/health‑tech sector.

None; the filing is U.S.‑focused.

Low; only investors in Tempus AI are directly impacted.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data platform.

  • Eric Lefkofsky

    CEO and Chairman of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.